91245-59-9

Usage

Uses

Used in Organic Synthesis:
(1-PHENYLCYCLOBUTYL)METHYLAMINE is used as a building block in organic synthesis for the preparation of various biologically active molecules. Its unique structure allows for the creation of complex organic compounds that can be further utilized in different applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (1-PHENYLCYCLOBUTYL)METHYLAMINE serves as a key component in the development of pharmaceuticals. Its incorporation into drug molecules can enhance their biological activity and therapeutic potential.
Used in Drug Development:
Due to its distinctive chemical properties, (1-PHENYLCYCLOBUTYL)METHYLAMINE holds promise in the development of new drugs. It can be used to design and synthesize novel pharmaceutical agents with improved efficacy and selectivity.
Used in Material Science:
The unique structure of (1-PHENYLCYCLOBUTYL)METHYLAMINE also suggests potential applications in material science. It may contribute to the development of new materials with specific properties, such as improved stability or reactivity.
Safety Considerations:
It is crucial to handle (1-PHENYLCYCLOBUTYL)METHYLAMINE with care and adhere to proper safety protocols when working with it in a laboratory setting. This ensures the safety of researchers and the integrity of the experiments conducted.

InChI:InChI=1/C11H15N/c12-9-11(7-4-8-11)10-5-2-1-3-6-10/h1-3,5-6H,4,7-9,12H2

Upstream product

• 14377-68-5 1-phenylcyclobutanecarbonitrile 

Downstream Products

• 551943-96-5 (4β,5α)-12-Hydroxy-N-[(1-phenylcyclobutyl)methyl]podocarpa-8,11,13-trien-16-amide 
• 850875-63-7 (1-Phenyl-cyclobutylmethyl)-carbamic acid methyl ester 
• 850875-62-6 4,4-siprocyclobutyl-1,2,3,4-tetrahydro-isoquinoline 

Relevant academic research and scientific papers

MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Therapeutic compounds for treating dyslipidemic conditions

Compounds of Formula I and the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of: (a) Formula Ia ?and (b) Formula Ib are novel LXR agonists and are useful in the treatment of dyslipidemic conditions p

Pyrazinone protease inhibitors

Pyrazinone compounds are described, including compounds of the Formula I: wherein X is O, NR11or CH═N, R3-R11, Ra, Rb, Rc, W, m, and n are set forth in the specification, as well as hydrate

Substituted sulfonamides, process of preparation and medicines containing same

The present invention concerns new substituted sulfonamides, and the physiologically acceptable salts possibly in the form of complexes, esters and amides thereof, represented by the formula: STR1

Inhibitors of Acyl-CoA:Cholesterol Acyltransferase. 4. A Novel Series of Urea ACAT Inhibitors as Potential Hypocholesterolemic Agents

We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT).This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia.For this series of compounds, the in vitro ACAT inhibitory activity was improved by increasing the bulk of the 2,6-substituents on the phenyl ring.Additionally, we found that spacing of the aromatic rings was critical for ACAT inhibitory activity.A phenyl ring five atoms away from the requiste 2,6-diisopropylphenyl moiety was optimal for in vitro activity.Substitution α to the N'-phenyl moiety enhanced in vitro potency.In the case of phenylcycloalkyl ureas, ACAT inhibitory activity was independent of the size of the cycloalkyl ring.From this series of analogs, compound 25, which had excellent in vitro potency for inhibiting ACAT, was found to lower plasma cholesterol by 73percent in vivo when administrated in the diet at 50 mg/kg in an animal model of hypercholesterolemia.In this model, compound 25 lowered plasma cholesterol dose dependently and was as efficacious as the Lederle ACAT inhibitor CL 277082.